Oncology Business Management | Specialty

The business management condition center is a comprehensive resource for clinical news and expert insights on business management. Read more at OncLive.

Revisit Every OncLive On Air Episode From October 2024

November 1st 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in October 2024.

Medicare Drug Price Negotiations Will Have Domino Effect for Community Oncology Practices

September 24th 2024

Medicare drug price negotiations may impact community oncology practices, leading to potential changes in drug access, reimbursement, and patient care strategies.

AI Is Poised to Influence Several Areas of Cancer Care With Some Fine-Tuning

September 23rd 2024

Krishnansu S. Tewari, MD, and Kimberly Futch, MBA, detail considerations with AI programs, and roles AI may have in early diagnosis, time reduction in the examination of scans, and more.

Medicare Drug Price Negotiation Program Will Result in Financial Burdens for Community Oncology Practices

September 5th 2024

Debra Patt, MD, PhD, MBA, FASCO, highlights considerations with financial burdens that will be placed on community providers and oncology practices.

A Decrease in Innovation Is a Large Concern With New IRA Policies in Oncology

September 4th 2024

Jeff Patton, MD, details considerations with the Medicare Drug Price Negotiation Program Draft Guidance and its effects in the community setting.

Vice President of COA Unpacks Effects of the Medicare Drug Price Negotiation Program in the Community

September 3rd 2024

Debra Patt, MD, PhD, MBA, FASCO, details how the Medicare Drug Price Negotiation Program Draft Guidance will affect community oncologists and practices.

Merck to Discontinue KEYNOTE-867 and KEYNOTE-630 Trials of Pembrolizumab in NSCLC, CSCC

August 29th 2024

The phase 3 KEYNOTE-867 and KEYNOTE-630 trials evaluating pembrolizumab in NSCLC and CSCC, respectively, have been discontinued by Merck.

Revisit Every OncLive On Air Episode From July 2024

July 31st 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in July 2024.

340B Drug Pricing Program Ostensibly Improves Cancer Care but Carries Unforeseen Consequences

July 22nd 2024

Kassem Faraj, MD, details the 340B Drug Pricing program and data from a study examining participation in the program for patients with advanced prostate cancer.

Carving Out a Career in Medical Education

July 16th 2024

Sam Brondfield, MD, MA, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses careers in medical education.

Revisit Every OncLive On Air Episode From June 2024

July 1st 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in June 2024.

Leveraging Managed Service Organizations to Provide More Affordable, Personalized Cancer Care

May 17th 2024

To combat the rising costs of cancer care, clinicians are partnering with managed service organizations to handle the business aspects of practice.

Husband and Wife Duo Pursue Medicine Together

May 2nd 2024

Manmeet Singh Ahluwalia, MD, and his wife, Harneet Kaur Walia, MD, say that they learn from each other’s experiences and share in successes.

Dr Arianna Gianakos: Innovation and Trailblazing Paths in Orthobiologics

April 23rd 2024

Arianna Gianakos, DO, discusses the innovation in orthobiologics and trailblazing paths in equity and advocacy.

Quality Over Quantity: What Concierge Medicine Can Offer to Patients With Cancer and Employers

April 19th 2024

The current health care economy has driven many employers to self-funding models to offer affordable health care coverage to employees.

The Critical Nature of Decision-Making in the Development of Phase 3 Clinical Trials

April 12th 2024

Randomized trials are widely recognized to play a pivotal role in the decision-making associated with the establishment of clinical guidelines.

Patient Insurance Status and Out-of-Pocket Costs Affect Genomic Testing Frequency

April 2nd 2024

As genomic testing becomes ubiquitous in cancer care, some patients experience out-of-pocket costs that may affect oncologists’ genetic testing decisions.

Tampa General Hospital Cancer Institute Celebrates 2 Years of Growth and Innovation

January 19th 2024

Tampa General Hospital Cancer Institute has experienced much growth since its establishment, in terms of attracting talent and expanding their footprint.

Public Trust in Science and the Future of Cancer Care Is Crucial

January 12th 2024

Maurie Markman, MD, details how public trust is critical in the future of cancer care, diving into what leads to mistrust and misinformation today.

Westin Testifies to Senate Finance Committee on Cancer Drug Shortage

December 5th 2023

Shortages of several anticancer drugs continue to negatively impact clinicians’ ability to deliver the best possible care to patients.